Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — In patients with metabolic-associated steatotic liver disease or metabolic-associated ...

The researchers found that patients taking GLP-1 RAs had a significantly reduced incidence of revision FESS versus the non-GLP-1 RA group at one-year (risk ratio [RR], 0.64) and five-year follow-up ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients who received glucagon-like peptide-1 receptor ...

By Tarun Sai Lomte An expert editorial suggests that widely used diabetes and obesity drugs may help close the long-standing ...

The National Academies’ Forum on Neuroscience and Nervous Systems Disorders hosted a workshop on September 10, 2024, they brought together diverse perspectives to examine the promising but ...

The Phase 1 trial was a randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending ...

Treatment with DD01 treatment reduced hepatic steatosis by more than 50% in 4 weeks, according to phase 1 data. The Food and Drug Administration (FDA) has granted Fast Track designation to DD01 for ...

Heart failure with preserved ejection fraction (HFpEF) is associated with hypertension and metabolic disorders and remains one of the main challenges for cardiovascular risk management. Researchers ...